"Tamoxifen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.
| Descriptor ID |
D013629
|
| MeSH Number(s) |
D02.455.426.559.389.150.700.900
|
| Concept/Terms |
ICI-46474- ICI-46474
- ICI 46474
- ICI46474
- ICI-46,474
- ICI 46,474
- ICI46,474
|
Below are MeSH descriptors whose meaning is more general than "Tamoxifen".
Below are MeSH descriptors whose meaning is more specific than "Tamoxifen".
This graph shows the total number of publications written about "Tamoxifen" by people in this website by year, and whether "Tamoxifen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2010 | 1 | 1 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 2 | 0 | 2 |
| 2019 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tamoxifen" by people in Profiles.
-
Prolylcarboxypeptidase promotes IGF1R/HER3 signaling and is a potential target to improve endocrine therapy response in estrogen receptor positive breast cancer. Cancer Biol Ther. 2022 Dec 31; 23(1):1-10.
-
Sensory Neuron-Specific Deletion of Tropomyosin Receptor Kinase A (TrkA) in Mice Abolishes Osteoarthritis (OA) Pain via NGF/TrkA Intervention of Peripheral Sensitization. Int J Mol Sci. 2022 Oct 11; 23(20).
-
Fatty acid oxidation and autophagy promote endoxifen resistance and counter the effect of AKT inhibition in ER-positive breast cancer cells. J Mol Cell Biol. 2021 09 11; 13(6):433-444.
-
Nipple changes in an 85-year-old man. CMAJ. 2019 02 04; 191(5):E135.
-
MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers. Proc Natl Acad Sci U S A. 2014 Dec 09; 111(49):17606-11.
-
Critical roles for nitric oxide and ERK in the completion of prosurvival autophagy in 4OHTAM-treated estrogen receptor-positive breast cancer cells. Cancer Lett. 2014 Oct 28; 353(2):290-300.
-
Estrogen receptor-? expression and pharmacological targeting in bladder cancer. Oncol Rep. 2013 Jul; 30(1):131-8.
-
GM-CSF controls nonlymphoid tissue dendritic cell homeostasis but is dispensable for the differentiation of inflammatory dendritic cells. Immunity. 2012 Jun 29; 36(6):1031-46.
-
Adjuvant endocrine therapy for breast cancer. Oncology (Williston Park). 2012 Jun; 26(6):541-7, 550, 552 passim.
-
Peyronie's disease: review of nonsurgical treatment options. Urol Clin North Am. 2011 May; 38(2):195-205.